Crystal forms of thiazole compound and application thereof
Disclosed by the present invention are a crystal form A of a compound represented by formula (I), a compound represented by formula (II) and a crystal form B thereof, as well as an application of the crystal form A of the compound represented by formula (I), the compound represented by formula (II) and the crystal form B thereof in the preparation of a drug for the treatment diseases associated with the herpes simplex virus.
1. A crystal form A of compound of formula (I), wherein the X-ray powder diffraction pattern thereof has characteristic diffraction peaks at the following 2θ angles: 10.81±0.2°, 15.97±0.2°, and 21.69±0.2°,
2. The crystal form A according to claim 1 , wherein the X-ray powder diffraction pattern thereof has characteristic diffraction peaks at the following 2θ angles: 10.81±0.2°, 13.03±0.2°, 15.97±0.2°, 18.48±0.2°, 21.69±0.2°, 23.78±0.2°, 25.14±0.2°, and 26.96±0.2°.
3. The crystal form A according to claim 2 , wherein the XRPD pattern thereof is shown in FIG. 1 .
4. The crystal form A according to claim 1 , wherein the differential scanning calorimetry curve thereof has a starting point of the endothermic peak at 216.04±3° C.
5. The crystal form A according to claim 4 , wherein the DSC curve thereof is shown in FIG. 2 .
6. The crystal form A according to claim 1 , wherein the thermogravimetric analysis curve thereof has a weight loss of up to 0.4442% at 120±3° C. and up to 2.4492% at 204±3° C.
7. The crystal form A according to claim 6 , wherein the TGA curve thereof is shown in FIG. 3 .
8. A crystal form B of a compound of formula (II),
wherein the X-ray powder diffraction pattern thereof has characteristic diffraction peaks at the following 2θ angles: 10.17±0.2°, 11.85±0.2°, and 15.94±0.2°.
9. The crystal form B according to claim 8 , wherein the X-ray powder diffraction pattern thereof has characteristic diffraction peaks at the following 2θ angles: 8.46±0.2°, 10.17±0.2°, 11.85±0.2°, 13.98±0.2°, 15.94±0.2°, 20.39±0.2°, 21.32±0.2°, and 23.78±0.2°.
10. The crystal form B according to claim 9 , wherein the XRPD pattern thereof is shown in FIG. 4 .
11. The crystal form B according to 8 , wherein the differential scanning calorimetry curve thereof has a starting point of the endothermic peak at 185.89±3° C.
12. The crystal form B according to claim 11 , wherein the DSC curve thereof is shown in FIG. 5 .
13. The crystal form B according to claim 8 , wherein the thermogravimetric analysis curve thereof has a weight loss of up to 0.7160% at 187.16±3° C.
14. The crystal form B according to claim 13 , wherein the TGA curve thereof is shown in FIG. 6 .
15. A method of treating a disease related to herpes simplex virus in a subject in need thereof, comprising administering to the subject the crystal form A of the compound of formula (I) according to claim 1 .
16. A method of treating a disease related to herpes simplex virus in a subject in need thereof, comprising administering to the subject the crystal form B of the compound of formula (II) according to claim 8 .
17. The crystal form A according to claim 4 , wherein the thermogravimetric analysis curve thereof has a weight loss of up to 0.4442% at 120±3° C. and up to 2.4492% at 204±3° C.
18. The crystal form B according to claim 11 , wherein the thermogravimetric analysis curve thereof has a weight loss of up to 0.7160% at 187.16±3° C.